Abstract:BackgroundInhibition of prostate smooth muscle contraction by α1‐adrenoceptor antagonists (α1‐blockers) is a first‐line medical treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Increased smooth muscle tone in the hyperplastic prostate may drive urethral obstruction, resulting in bladder outlet obstruction and voiding symptoms. However, efficacy of α1‐blockers is limited, as non‐adrenergic mediators including endothelin‐1 and thromboxane A2 (TXA2) increase prostate smooth muscle tension in parallel to α1‐adrenoceptors. This may maintain urethral obstruction despite therapy with α1‐blockers. Consequently, future treatment options with higher efficacy need to target α1‐adrenergic and non‐adrenergic contractions simultaneouly. Recently, several compounds were reported to inhibit adrenergic or neurogenic prostate contractions, however, their effects on non‐adrenergic contraction are unknown. Here, we examined effects of inhibitors for Rac‐GTPase, Src family kinases (SFKs), and p21‐activated kinases (PAKs) on non‐adrenergic prostate contractions.MethodsProstate tissues were obtained from radical prostatectomy. Contractions were studied in an organ bath. Viability of cultured stromal cells was assessed by CCK‐8 assay.ResultsInhibition of α1‐adrenergic contractions by Rac inhibitors EHT1864 (100 μM) and NSC23766 (100 μM), and SFK inhibitors AZM475721 (10 μM) and PP2 (10 μM) was confirmed by inhibition of methoxamine‐induced contractions. No effects of the PAK inhibitors FRAX486 (30 μM) and IPA3 (300 μM) on α1‐adrenergic contraction were confirmed by absent effects on methoxamine‐inuced contractions. EHT1864 caused inhibition of endothelin‐1‐ and U46619‐induced contractions. EHT1864 reduced the viability of stromal cells concentration‐ and time‐dependently. EHT1864 attenuated KCl‐induced contractions of prostate strips only slightly, so that toxic effects may not account alone for inhibition of agonist‐induced contractions. NSC23766 inhibited U46619‐induced contractions, but not endothelin‐1‐induced contractions. AZM475271 had no effects on endothelin‐1‐ or U46619‐induced contractions, while PP2 inhibited U46619‐ but not endothelin‐1‐induced contractions. FRAX486 caused inhibition of U46619‐induced contractions. IPA3 inhibited U46619‐, but not endothelin‐1‐induced contractions.ConclusionsOf all six inhibitors, EHT1864 seems to be most promising from a translational point of view, as it inhibited TXA2‐ and endothelin‐1‐induced besides α1‐adrenergic prostate contractions. This reflects divergent pharmacologic profiles of EHT1864 and NSC23766, although both are Rac‐GTPase inhibitors. In vivo, urodynamic effects of EHT1864 and possibly of FRAX486 may exceed those of α1‐blockers.

Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-1-carboxylate monohydrate on smooth muscle preparations

In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist

Distinct effects of z-335, a new thromboxane A2 receptor antagonist, on rabbit platelets and aortic smooth muscle

Effect of 3-substituted 1,4-benzodiazepin-2-ones on maximal normalized rate of bradykinin-induced smooth muscle contraction in the presence of calcium channel blockers

Effect of 3-substituted 1,4-benzodiazepin-2-ones on bradykinin-induced smooth muscle contraction

Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers

Inhibition of Vasoconstriction by the Thromboxane A2 Antagonist GR32191B in the Human Radial Artery.

Effect of Thromboxane A2 Antagonist GR32191B on Prostanoid and Nonprostanoid Receptors in the Human Internal Mammary Artery

soprostanes constrict human radial artery by timulation of thromboxane receptors , Ca 2 release , nd RhoA activation

Pharmacologic profile of endothelinA/B antagonist, [Thr18, gamma methyl Leu19]endothelin-1.

Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework

A Novel Thromboxane Receptor Antagonist, Nstpbp5185, Inhibits Platelet Aggregation and Thrombus Formation in Animal Models

Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that

MC-002 exhibits positive effects against platelets aggregation and endothelial dysfunction through thromboxane A2 inhibition.

A Robust Bioassay of the Human Bradykinin B2 Receptor that Extends Molecular and Cellular Studies: The Isolated Umbilical Vein

Inhibition of Neurogenic Contractions in Renal Arteries and of Cholinergic Contractions in Coronary Arteries by the Presumed Inhibitor of ADP-ribosylation Factor 6, NAV2729

TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1

NEW STRATEGIES FOR INHIBITION OF NON-ADRENERGIC PROSTATE SMOOTH MUSCLE CONTRACTION BY PHARMACOLOGIC INTERVENTION

Effects of TAK-480, a novel tachykinin NK(2)-receptor antagonist, on visceral hypersensitivity in rabbits and ricinoleic acid-induced defecation in guinea pigs

The effect of first-in-class small molecule RhoA inhibitor, HL07, on the phenylephrine-induced artery contraction.

[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors